莫德纳于2026年7月与Arbutus和Genevant达成专利纠纷，支付9.5亿美元，若上诉失败，可能额外赔偿13亿美元。 Moderna settled a patent dispute with Arbutus and Genevant, paying $950 million in July 2026, with possible additional $1.3 billion if appeal fails.

莫德纳已与Arbutus生物制药公司和Genevant Sciences就其新冠疫苗中使用的脂质纳米颗粒技术达成全球专利争议，双方同意于2026年7月支付9.5亿美元，若上诉失败，可能额外支付13亿美元。 Moderna has settled a global patent dispute with Arbutus Biopharma and Genevant Sciences over lipid nanoparticle technology used in its COVID-19 vaccine, agreeing to pay $950 million in July 2026 with a potential additional $1.3 billion if an appeal fails. 协议解决了所有法律索赔,取消了未来的使用费义务,并消除了长期的不确定性,使现代公司能够集中精力开发下一代疫苗和疗法。 The deal resolves all legal claims, eliminates future royalty obligations, and removes long-term uncertainty, allowing Moderna to focus on developing next-generation vaccines and therapies. 该公司预计将以4.5至50亿美元的现金和高达9亿美元的可用信贷来结束2026年。 The company expects to end 2026 with $4.5 to $5.0 billion in cash and up to $900 million in available credit. 其股票在宣布后上涨超过10%。 Its stock rose over 10% after the announcement.